UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026866
Receipt number R000030829
Scientific Title Impact on immune function by ingesting Natto
Date of disclosure of the study information 2017/04/05
Last modified on 2017/04/05 12:11:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Impact on immune function by ingesting Natto

Acronym

Impact on immune function by ingesting Natto

Scientific Title

Impact on immune function by ingesting Natto

Scientific Title:Acronym

Impact on immune function by ingesting Natto

Region

Japan


Condition

Condition

Healthy Adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluate the influence on immune function when feeding Natto for 8 weeks, for middle-aged and elderly subjects whose immune function tends to decline.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Secretory immunoglobulin A (S-IgA)

Key secondary outcomes

Tiredness/Feeling (VAS)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Natto

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

Healthy men and women of ages 50 to 64 years old

Key exclusion criteria

1. Persons who have symptoms of hay fever and perennial allergic rhinitis
2. Persons who have diseases in the oral cavity such as periodontal disease or dry mice
3. Person who has heart disease
4. Person who take warfarin
5. Person who has a history of diabetes, liver disease, kidney disease, gastrointestinal disease, peripheral vascular disease, other severe disease
6. Persons who show impaired cardiopulmonary function
7. Persons who liver function and renal function test values show abnormalities
8. Persons who have had surgery on the gastrointestinal tract
9. Currently, those with a disorder under treatment
10. Persons who have food or drug allergy
11. Persons who do intense sports or are on a diet
12. Persons who are taking health foods, quasi medical items, medicines (including OTC, prescription medicine) containing ingredients contained in the test food
13. Persons who consume excess alcohol or can not abstinence from the day before the test until the day
14. Persons who are pregnant, or persons who are planning to become pregnant or breastfeeding during the study period
15. Persons who are participating in the other study or planning to participate during the study period
16. Persons who judged inappropriate by the study responsible doctor for other reasons

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Naoki Miura

Organization

Miura Clinic, Medical Corporation Kanonkai

Division name

Internal Medicine

Zip code


Address

9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan

TEL

06-6135-5200

Email

info@miura-cl.jp


Public contact

Name of contact person

1st name
Middle name
Last name Makoto Terashima

Organization

Oneness Support Co., Ltd.

Division name

Clinical trial Division

Zip code


Address

9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan

TEL

06-4801-8917

Homepage URL


Email

mterashima@miura-cl.jp


Sponsor or person

Institute

Takanofoods Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Takanofoods Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Miura Clinic, Medical Corporation Kanonkai
Oneness Support Co., Ltd.

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 02 Month 23 Day

Date of IRB


Anticipated trial start date

2017 Year 04 Month 10 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 04 Month 05 Day

Last modified on

2017 Year 04 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030829


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name